Proteinuria and baseline renal function predict mortality and renal outcomes after sirolimus therapy in liver transplantation recipients

Table 2 Indications of sirolimus therapy

Variable	N (%)
Renal dysfunction^a	318 (55.2)
HCC
Prophylaxis	93 (16.1)
Recurrence	21 (3.6)
Non-hepatic tumors	18 (3.1)
Biopsy proved acute/chronic rejection	84 (14.6)
Neurotoxicity	5 (0.9)
Other side effects from immunosuppressants	37 (6.4)

^aDefined by physician’s criteria or eGFR <60 mL/min/1.73 m² without other reasons for SRL use

ISSN: 1471-230X